Diabetes Care, Vol 21, Issue 7 1122-1128, Copyright © 1998 by American Diabetes Association

ARTICLES

Direct medical costs of complications resulting from type 2 diabetes in the U.S

JA O'Brien, LA Shomphe, PL Kavanagh, G Raggio and JJ Caro
Caro Research, Concord, MA 01742, USA. jobrien@caroresearch.com

OBJECTIVE: To estimate direct medical costs of managing the complications of type 2 diabetes. RESEARCH DESIGN AND METHODS: Costs were estimated for 15 diabetic complications by applying unit costs to typical resource-use profiles. Resource used and unit costs were estimated from many sources, including acute care discharge databases, clinical guidelines, government reports, fee schedules, and peer-reviewed literature. For each complication, the event costs are those associated with resource use that is specific to the acute episode and any subsequent care occurring in the 1st year. State costs are the annual costs of continued management. All costs are expressed in 1996 U.S. dollars. RESULTS: As expected, the more severe or debilitating events, such as acute myocardial infarction ($27,630 event cost; $2,185 state cost), generate a greater financial burden than do early-stage complications, such as microalbuminuria ($62 event cost; $14 state cost). Yet, complications that are initially relatively low in cost (e.g., microalbuminuria) can progress to more costly advanced stages (e.g., end-stage renal disease, $53,659 state cost); therefore, minor complications should also be considered in any economic analysis of diabetes. CONCLUSIONS: The recent literature has lacked cost estimates that may be readily translated into patient-level cost inputs for an economic model. Emerging therapies that may reduce the incidence of some diabetic complications will need to be scrutinized economically in today's cost-conscious environment. The cost estimates from this study provide one piece of the economic analysis needed to evaluate these new interventional therapies.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. Cronquist Christensen and D. Remler Information and Communications Technology in Chronic Disease Care: What Are the Implications for Payment? Med Care Res Rev, April 1, 2007; 64(2): 123 - 147. [Abstract] [PDF]

				L. B. Russell, E. Valiyeva, S. H. Roman, L. M. Pogach, D.-C. Suh, and M. M. Safford Hospitalizations, Nursing Home Admissions, and Deaths Attributable to Diabetes Diabetes Care, July 1, 2005; 28(7): 1611 - 1617. [Abstract] [Full Text] [PDF]

				J. Oliva, F. Lobo, B. Molina, and S. Monereo Direct Health Care Costs of Diabetic Patients in Spain Diabetes Care, November 1, 2004; 27(11): 2616 - 2621. [Abstract] [Full Text] [PDF]

				H. Eyre, R. Kahn, R. M. Robertson, and and the ACS/ADA/AHA Collaborative Writing Committe Preventing Cancer, Cardiovascular Disease, and Diabetes: A Common Agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association Stroke, August 1, 2004; 35(8): 1999 - 2010. [Abstract] [Full Text] [PDF]

				H. Eyre, R. Kahn, R. M. Robertson, and the ACS/ADA/AHA Collaborative Writing Committe, N. G. Clark, C. Doyle, T. Gansler, T. Glynn, Y. Hong, R. A. Smith, et al. Preventing Cancer, Cardiovascular Disease, and Diabetes: A Common Agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association CA Cancer J Clin, July 1, 2004; 54(4): 190 - 207. [Abstract] [Full Text] [PDF]

				H. Eyre, R. Kahn, and R. M. Robertson Preventing Cancer, Cardiovascular Disease, and Diabetes: A common agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association Diabetes Care, July 1, 2004; 27(7): 1812 - 1824. [Abstract] [Full Text] [PDF]

				H. Eyre, R. Kahn, R. M. Robertson, the ACS/ADA/AHA Collaborative Writing Committee, ACS/ADA/AHA Collaborative Writing Committee Member, N. G. Clark, C. Doyle, Y. Hong, T. Gansler, T. Glynn, et al. Preventing Cancer, Cardiovascular Disease, and Diabetes: A Common Agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association Circulation, June 29, 2004; 109(25): 3244 - 3255. [Abstract] [Full Text] [PDF]

				T. J. Hoerger, R. Harris, K. A. Hicks, K. Donahue, S. Sorensen, and M. Engelgau Screening for Type 2 Diabetes Mellitus: A Cost-Effectiveness Analysis Ann Intern Med, May 4, 2004; 140(9): 689 - 699. [Abstract] [Full Text] [PDF]

				D. Fetterolf and R. West The Business Case for Quality: Combining Medical Literature Research with Health Plan Data to Establish Value for Nonclinical Managers American Journal of Medical Quality, March 1, 2004; 19(2): 48 - 55. [Abstract] [PDF]

				M. Brandle, H. Zhou, B. R.K. Smith, D. Marriott, R. Burke, B. P. Tabaei, M. B. Brown, and W. H. Herman The Direct Medical Cost of Type 2 Diabetes Diabetes Care, August 1, 2003; 26(8): 2300 - 2304. [Abstract] [Full Text] [PDF]

				S. H. Simpson, P. Corabian, P. Jacobs, and J. A. Johnson The cost of major comorbidity in people with diabetes mellitus Can. Med. Assoc. J., June 24, 2003; 168(13): 1661 - 1667. [Abstract] [Full Text] [PDF]

				W. A. Jorgensen, B. J. Pollvka, and T. A. Lennie Perceived Adherence to Prescribed or Recommended Standards of Care Among Adults With Diabetes The Diabetes Educator, November 1, 2002; 28(6): 989 - 998. [Abstract] [PDF]

				R. R. McCandless Attributing Inpatient Medicare Costs to Diabetes Among the Texas Elderly Diabetes Care, November 1, 2002; 25(11): 1958 - 1963. [Abstract] [Full Text] [PDF]

				The CDC Diabetes Cost-effectiveness Group Cost-effectiveness of Intensive Glycemic Control, Intensified Hypertension Control, and Serum Cholesterol Level Reduction for Type 2 Diabetes JAMA, May 15, 2002; 287(19): 2542 - 2551. [Abstract] [Full Text] [PDF]

				J. Sidorov, R. Shull, J. Tomcavage, S. Girolami, N. Lawton, and R. Harris Does Diabetes Disease Management Save Money and Improve Outcomes? : A report of simultaneous short-term savings and quality improvement associated with a health maintenance organization-sponsored disease management program among patients fulfilling health employer data and information set criteria Diabetes Care, April 1, 2002; 25(4): 684 - 689. [Abstract] [Full Text] [PDF]

				J. J. Caro, A. J. Ward, and J. A. O'Brien Lifetime Costs of Complications Resulting From Type 2 Diabetes in the U.S. Diabetes Care, March 1, 2002; 25(3): 476 - 481. [Abstract] [Full Text] [PDF]

				G. A. Nichols and J. B. Brown The Impact of Cardiovascular Disease on Medical Care Costs in Subjects With and Without Type 2 Diabetes Diabetes Care, March 1, 2002; 25(3): 482 - 486. [Abstract] [Full Text] [PDF]

				S. Shea, J. Starren, R. S. Weinstock, P. E. Knudson, J. Teresi, D. Holmes, W. Palmas, L. Field, R. Goland, C. Tuck, et al. Columbia University's Informatics for Diabetes Education and Telemedicine (IDEATel) Project: Rationale and Design J. Am. Med. Inform. Assoc., January 1, 2002; 9(1): 49 - 62. [Abstract] [Full Text] [PDF]

				S. Ramsey, K. H. Summers, S. A. Leong, H. G. Birnbaum, J. E. Kemner, and P. Greenberg Productivity and Medical Costs of Diabetes in a Large Employer Population Diabetes Care, January 1, 2002; 25(1): 23 - 29. [Abstract] [Full Text] [PDF]

				J. Menzin, C. Langley-Hawthorne, M. Friedman, L. Boulanger, and R. Cavanaugh Potential Short-Term Economic Benefits of Improved Glycemic Control: A managed care perspective Diabetes Care, January 1, 2001; 24(1): 51 - 55. [Abstract] [Full Text]

				C. A. Polanczyk, K. M. Kuntz, D. B. Sacks, P. A. Johnson, and T. H. Lee Emergency Department Triage Strategies for Acute Chest Pain Using Creatine Kinase-MB and Troponin I Assays: A Cost-Effectiveness Analysis Ann Intern Med, December 21, 1999; 131(12): 909 - 918. [Abstract] [Full Text] [PDF]